GREENVILLE, S.C., Nov. 1 /PRNewswire-FirstCall/ -- Signalife, Inc. (“Company”), announced today that Robert L. Lux, Ph.D., Professor of Medicine, University of Utah School of Medicine, Division of Cardiology joined company’s Medical Advisory Board. The Medical Advisory Board -- which includes Andrea Natale, M.D. from Cleveland Clinic and Mitchell W. Krucoff, M.D. from Duke University -- provides Signalife management with guidance in determining the best strategy for development of technology and products. Dr. Lux has performed extensive research and is well published in the field of electrocardiographic mapping, cardiac repolarization and the visualization, characterization, and analysis of dynamic cardiac electrophysiologic phenomena.
Dr. Mitchell W. Krucoff, Signalife’s Medical Advisory Board member and the founder and Director of the Ischemia Monitoring Laboratory and eECG Core Laboratory at Duke Clinical Research Institute, the largest academic electronic ECG Core Laboratory in the world, stated: “Bob Lux is one of the world’s foremost ECG thought leaders, with both technical and clinical expertise. His perspective ranges from the most theoretical to the most practical. He is a great addition to the Signalife Medical Advisory Board.”
“Dr. Lux acceptance of this position speaks volumes for our company, its technology, its products, and its research and development team . . . and most of all, for its future,” remarked Pamela Bunes, the company Chief Executive Officer. We are delighted that such a distinguished expert in the field of electrocardiography has agreed to work with us and further the successful development of this technology into commercially available products.”
About Signalife, Inc.
Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient’s cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit http://www.signalife.com.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient, client or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. Additional risks are found in clientele acceptance of Signalife’s product-set. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission, but are significant and should be carefully evaluated by any and all investors.
Signalife, Inc.
CONTACT: Claire LaFrance, +1-864-233-2300
Web site: http://www.signalife.com/
